Disease Control Data, nr-axSpA

Review separate clinical trial data relating to the efficacy of RINVOQ® in non-radiographic axial spondyloarthritis patients. See Important Safety Info, including BOXED WARNING, and full Prescribing Info.

FDA Approval Of The First nr-AxSpA Biologics Projecting Regulatory Market Dynamics

Axial spondyloarthritis: concept, construct, classification and implications for therapy

Looking through the window of opportunity in axial spondyloarthritis? - ScienceDirect

Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis, Arthritis Research & Therapy

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial

Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: Data from the Swiss Clinical Quality Management cohort

Understanding differences between men and women with axial spondyloarthritis - ScienceDirect

Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients – baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice – topic of

Axial Spondyloarthritis, Ankylosing Spondylitis